Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies

Clinical Science
Dick C ChanGerald F Watts

Abstract

The metabolic syndrome encapsulates visceral obesity, insulin resistance, diabetes, hypertension and dyslipidaemia. Dyslipidaemia is a cardinal feature of the metabolic syndrome that accelerates the risk of cardiovascular disease. It is usually characterized by high plasma concentrations of triacylglycerol (triglyceride)-rich and apoB (apolipoprotein B)-containing lipoproteins, with depressed concentrations of HDL (high-density lipoprotein). However, lipoprotein metabolism is complex and abnormal plasma concentrations can result from alterations in the rates of production and/or catabolism of these lipoprotein particles. Our in vivo understanding of kinetic defects in lipoprotein metabolism in the metabolic syndrome has been achieved chiefly by ongoing developments in the use of stable isotope tracers and mathematical modelling. This review deals with the methodological aspects of stable isotope kinetic studies. The design of in vivo turnover studies requires considerations related to stable isotope tracer administration, duration of sampling protocol and interpretation of tracer data, all of which are critically dependent on the kinetic properties of the lipoproteins under investigation. Such models provide novel insight that ...Continue Reading

References

Jan 1, 1986·Methods in Enzymology·G SteinerD M Foster
Jun 1, 1995·Current Opinion in Lipidology·T D Watson
Jan 1, 1996·Methods in Enzymology·F KarpeG Steiner
Jun 1, 1996·Current Opinion in Lipidology·P HughD M Foster
Mar 1, 1997·Metabolism: Clinical and Experimental·B W Patterson
Apr 4, 1998·The American Journal of Cardiology·S M Grundy
Apr 29, 1998·Metabolism: Clinical and Experimental·P H BarrettD M Foster
Oct 22, 1998·Advances in Experimental Medicine and Biology·C Cobelli, D M Foster
Oct 24, 1998·Endocrinology and Metabolism Clinics of North America·H N Ginsberg
Apr 21, 1999·Progress in Lipid Research·D A Chappell, J D Medh
Dec 11, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·F K WeltyE J Schaefer
Feb 23, 2000·The Journal of Clinical Investigation·J TwiskA D Attie
Jul 6, 2000·Current Opinion in Lipidology·J B MarshE J Schaefer
Jul 15, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·F K WeltyE J Schaefer
Jan 9, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·A von EckardsteinG Assmann
May 16, 2001·Current Opinion in Lipidology·N S Shachter
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 10, 2002·Metabolism: Clinical and Experimental·K OuguerramT Magot
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Mar 2, 2002·Journal of Diabetes and Its Complications·Kerin O'Dea, Kevin G Rowley
May 17, 2002·Critical Reviews in Clinical Laboratory Sciences·John R Burnett, P Hugh R Barrett
Jun 5, 2002·Atherosclerosis. Supplements·Marja-Riitta Taskinen
Jul 30, 2002·Metabolism: Clinical and Experimental·Dick C ChanP Hugh R Barrett
Sep 18, 2002·Journal of Lipid Research·Kaspar K Berneis, Ronald M Krauss
Sep 28, 2002·Diabetes·Robert L HansonWilliam C Knowler
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Apr 30, 2003·Diabetes·Charles M AlexanderUNKNOWN National Cholesterol Education Program (NCEP)
Nov 19, 2003·Current Opinion in Lipidology·Julia Steinberger
Mar 9, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·H Bryan Brewer

❮ Previous
Next ❯

Citations

Mar 28, 2008·Current Diabetes Reports·Martin AdielsJan Borén
Jan 13, 2006·Current Opinion in Lipidology·Dick C ChanGerald F Watts
Jan 19, 2008·International Journal of Clinical Practice·D C ChanG F Watts
May 11, 2010·Atherosclerosis. Supplements·Gerald F Watts, Dick C Chan
Jun 6, 2009·Pharmacology & Therapeutics·Gerald F WattsDick C Chan
Jul 22, 2008·Metabolism: Clinical and Experimental·Rajasekhar Ramakrishnan, Janak D Ramakrishnan
Dec 7, 2011·Journal of Internal Medicine·J BorénM Adiels
Nov 6, 2008·Journal of Child Neurology·Hoda Yahya TomoumAhmed Hanafy Ali
Jun 11, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Martin AdielsMarja-Riitta Taskinen
Aug 22, 2006·European Journal of Clinical Investigation·E M M OoiP H R Barrett
Sep 14, 2007·Mass Spectrometry Reviews·Jean-Philippe GodinGérard Hopfgartner
Feb 16, 2010·Current Opinion in Lipidology·Theodore W K NgP Hugh R Barrett
Jul 16, 2010·Expert Opinion on Pharmacotherapy·Dick C Chan, Gerald F Watts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.